Mathematical modeling of viral kinetics: a tool to understand and optimize therapy
- PMID: 12691465
- DOI: 10.1016/s1089-3261(02)00063-6
Mathematical modeling of viral kinetics: a tool to understand and optimize therapy
Abstract
One theme that continues to emerge from these studies is the relevance and need for a strong IFN effectiveness. In the prediction studies, the importance of IFN effectiveness for eventual clearance of the virus is present. In the study by Layden et al, the relevance of the viral load at the end of the first phase and IFN effectiveness, to the subsequent second-phase viral decline, is discussed. In the recently developed triphasic model by Bergmann et al, it is illustrated how, theoretically, the viral load at the end of the first phase could impact the second-phase viral decline and eventual clearance of the virus. And, in the investigation into the difference in viral dynamics between African Americans and Caucasians, it appears that a strong effectiveness and first-phase log drop is crucial for virus eradication. More work needs to be completed to understand better why the effectiveness is so crucial for elimination of the virus, and why the effectiveness varies so significantly from one person to another, or from one genotype to another. In a rather short time, the study of viral kinetics has improved our understanding of HCV infection, especially in relation to treatment response. Information has been gleaned on the rapid turnover and clearance rate of the virus, the mode of action of IFN, and the dose-dependence of IFN in inhibiting viral production. Such information has been used to challenge the way we treat patients, understand the difference between nonresponders and responders, gain insight into possible mechanisms of treatment resistance, and predict treatment response. As newer drugs emerge, viral kinetic studies should be able to shed light on the dose-dependent efficacy and mode of action of these newer forms of therapy. The use of kinetics needs to be extended to other areas, such as the study and treatment of acute HCV infection as well as following liver transplantation (see article by Drs. Pawlotsky and Rosen). If the past is any indication of the usefulness of mathematical modeling and kinetics in the study of viruses, continued employment of these tools will only prove beneficial.
Similar articles
-
The kinetics of hepatitis C virus infection.Clin Liver Dis. 2001 Nov;5(4):917-30. doi: 10.1016/s1089-3261(05)70201-4. Clin Liver Dis. 2001. PMID: 11685801 Review.
-
First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline.J Viral Hepat. 2002 Sep;9(5):340-5. doi: 10.1046/j.1365-2893.2002.00377.x. J Viral Hepat. 2002. PMID: 12225328
-
Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.Gastroenterology. 2005 Feb;128(2):313-27. doi: 10.1053/j.gastro.2004.11.059. Gastroenterology. 2005. PMID: 15685543 Free PMC article. Clinical Trial.
-
Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.J Theor Biol. 2010 Dec 7;267(3):330-40. doi: 10.1016/j.jtbi.2010.08.036. Epub 2010 Sep 8. J Theor Biol. 2010. PMID: 20831874
-
Hepatitis C kinetics: mathematical modeling of viral response to therapy.Semin Liver Dis. 2000;20(2):173-83. doi: 10.1055/s-2000-9940. Semin Liver Dis. 2000. PMID: 10946422 Review.
Cited by
-
Human systems immunology: hypothesis-based modeling and unbiased data-driven approaches.Semin Immunol. 2013 Oct 31;25(3):193-200. doi: 10.1016/j.smim.2012.11.003. Epub 2013 Jan 29. Semin Immunol. 2013. PMID: 23375135 Free PMC article. Review.
-
Nonresponse to treatment for hepatitis C: current management strategies.Drugs. 2008;68(1):27-42. doi: 10.2165/00003495-200868010-00003. Drugs. 2008. PMID: 18081371 Review.
-
Innate immunity plays a key role in controlling viral load in COVID-19: mechanistic insights from a whole-body infection dynamics model.medRxiv [Preprint]. 2020 Nov 5:2020.10.30.20215335. doi: 10.1101/2020.10.30.20215335. medRxiv. 2020. Update in: ACS Pharmacol Transl Sci. 2020 Dec 30;4(1):248-265. doi: 10.1021/acsptsci.0c00183. PMID: 33173913 Free PMC article. Updated. Preprint.
-
A mathematical model of HIV dynamics in the presence of a rescuing virus with replication deficiency.Theory Biosci. 2011 Jun;130(2):127-34. doi: 10.1007/s12064-011-0119-y. Epub 2011 Jan 29. Theory Biosci. 2011. PMID: 21279471
-
Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment.J Infect Dis. 2009 Sep 15;200(6):866-76. doi: 10.1086/605475. J Infect Dis. 2009. PMID: 19673650 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous